Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Operations: 2013-2025

Historic Cash from Operations for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to -$50.7 million.

  • Ocular Therapeutix's Cash from Operations fell 38.75% to -$50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$190.1 million, marking a year-over-year decrease of 61.48%. This contributed to the annual value of -$134.7 million for FY2024, which is 91.75% down from last year.
  • Per Ocular Therapeutix's latest filing, its Cash from Operations stood at -$50.7 million for Q3 2025, which was up 8.17% from -$55.2 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Cash from Operations peaked at -$7.7 million during Q3 2023, and registered a low of -$55.2 million during Q2 2025.
  • For the 3-year period, Ocular Therapeutix's Cash from Operations averaged around -$32.3 million, with its median value being -$33.9 million (2024).
  • As far as peak fluctuations go, Ocular Therapeutix's Cash from Operations soared by 45.77% in 2022, and later plummeted by 372.83% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Cash from Operations (Quarterly) stood at -$15.2 million in 2021, then decreased by 11.91% to -$17.0 million in 2022, then slumped by 32.41% to -$22.5 million in 2023, then tumbled by 75.60% to -$39.4 million in 2024, then tumbled by 38.75% to -$50.7 million in 2025.
  • Its Cash from Operations was -$50.7 million in Q3 2025, compared to -$55.2 million in Q2 2025 and -$44.7 million in Q1 2025.